| Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) (NCT05461430) | Travera Inc | 2022-07-15 |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (NCT05451849) | TCR2 Therapeutics | 2022-06-21 |
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion (NCT05245500) | Bristol-Myers Squibb | 2022-06-09 |
| Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors (NCT05311618) | NGM Biopharmaceuticals, Inc | 2022-05-11 |
| A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors (NCT05070247) | Takeda | 2022-04-14 |
| Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma (NCT05278975) | RS Oncology LLC | 2022-03-31 |
| Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors (NCT05215574) | NGM Biopharmaceuticals, Inc | 2022-03-31 |
| A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors (NCT05238883) | HiFiBiO Therapeutics | 2022-03-10 |
| First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies (NCT05627960) | A&G Pharmaceutical Inc. | 2022-02-14 |
| Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma (NCT04429204) | Jonsson Comprehensive Cancer Center | 2021-12-01 |
| A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma (NCT05041062) | University of Chicago | 2021-12-01 |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing (NCT04981119) | A2 Biotherapeutics Inc. | 2021-10-29 |
| Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma (NCT04840615) | National Cancer Institute (NCI) | 2021-06-11 |
| Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies (NCT04913337) | NGM Biopharmaceuticals, Inc | 2021-06-09 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment (NCT04028479) | Taproot Health | 2021-05-05 |
| Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome (NCT04431024) | National Cancer Institute (NCI) | 2021-03-30 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors (NCT04272034) | Incyte Corporation | 2021-03-26 |
| Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors (NCT04665206) | Vivace Therapeutics, Inc | 2021-03-24 |
| Olaparib in Patients With HRD Malignant Mesothelioma (NCT04515836) | University of Chicago | 2021-02-19 |
| DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (NCT04334759) | PrECOG, LLC. | 2021-02-18 |
| UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC (NCT04940637) | University of Turin, Italy | 2020-12-23 |
| Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity (NCT04631731) | Western Sydney Local Health District | 2020-12-15 |
| Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders (NCT02748798) | Thunder Bay Regional Health Research Institute | 2020-11-10 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors (NCT04242199) | Incyte Corporation | 2020-09-04 |
| The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance (NCT04450043) | Massachusetts General Hospital | 2020-08-01 |
| Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (NCT04301011) | Turnstone Biologics, Corp. | 2020-06-02 |
| αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors (NCT04489862) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2020-05-13 |
| Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NCT04300244) | Åslaug Helland | 2020-05-04 |
| Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels (NCT04537715) | Epizyme, Inc. | 2020-04-23 |
| 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours (NCT04375267) | Vastra Gotaland Region | 2020-04-23 |
| A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma (NCT04214015) | ProgenaBiome | 2020-03-02 |
| Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors (NCT03023319) | Nagla Abdel Karim | 2019-12-10 |
| A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17) (NCT04153565) | Merck Sharp & Dohme LLC | 2019-12-09 |
| Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers (NCT03935893) | Udai Kammula | 2019-12-03 |
| Stereotactic Magnetic Resonance Guided Radiation Therapy (NCT04115254) | Dana-Farber Cancer Institute | 2019-10-22 |
| Phase I Trial HIPEC With Nal-irinotecan (NCT04088786) | Stony Brook University | 2019-10-22 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (NCT03983954) | NeoTX Therapeutics Ltd. | 2019-10-10 |
| Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma (NCT03918252) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2019-10-02 |
| Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases (NCT02859415) | National Cancer Institute (NCI) | 2019-08-08 |
| First-in-human Study of S-588210 (S-488210+S-488211) (NCT04316689) | Shionogi | 2019-07-30 |
| Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma (NCT04040231) | Memorial Sloan Kettering Cancer Center | 2019-07-24 |
| A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease (NCT04031469) | ProgenaBiome | 2019-07-11 |
| Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors (NCT04234113) | SOTIO Biotech AG | 2019-06-13 |
| Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies (NCT03881488) | Compass Therapeutics | 2019-05-17 |
| Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (NCT03907852) | TCR2 Therapeutics | 2019-04-15 |
| Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 (NCT03830229) | National Cancer Institute (NCI) | 2019-03-13 |
| Dose Individualization of Pemetrexed - IMPROVE-I (NCT03656549) | Radboud University Medical Center | 2019-02-01 |
| Dose Individualization of Pemetrexed - IMPROVE-III (NCT03655834) | Radboud University Medical Center | 2019-02-01 |
| Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma (NCT03644550) | National Cancer Institute (NCI) | 2018-12-04 |
| Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers (NCT03683680) | Dana-Farber Cancer Institute | 2018-10-31 |
| Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma (NCT03867578) | University of Chicago | 2018-10-10 |
| PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors (NCT03685591) | Pfizer | 2018-10-04 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies (NCT03652077) | Incyte Corporation | 2018-09-24 |
| A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma (NCT04056026) | ProgenaBiome | 2018-09-18 |
| A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) (NCT03207347) | University of Florida | 2018-08-13 |
| Olaparib in People With Malignant Mesothelioma (NCT03531840) | National Cancer Institute (NCI) | 2018-07-11 |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (NCT03517488) | Xencor, Inc. | 2018-07-10 |
| DENdritic Cell Immunotherapy for Mesothelioma (NCT03610360) | Amphera BV | 2018-06-21 |
| A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies (NCT03538028) | Incyte Biosciences International Sàrl | 2018-06-18 |
| VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (NCT03556228) | VM Oncology, LLC | 2018-06-08 |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies (NCT03638206) | Shenzhen BinDeBio Ltd. | 2018-03-01 |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma (NCT03436732) | National Cancer Institute (NCI) | 2018-02-28 |
| Cardiac MRI Biomarker Testing (GCC 1618) (NCT02688166) | University of Maryland, Baltimore | 2018-02-01 |
| Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma (NCT03319537) | Memorial Sloan Kettering Cancer Center | 2017-10-05 |
| Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (NCT02709512) | Polaris Group | 2017-08-01 |
| Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) (NCT02758587) | NHS Greater Glasgow and Clyde | 2017-07-04 |
| Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (NCT02899195) | PrECOG, LLC. | 2017-06-13 |
| A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma (NCT03075527) | Dana-Farber Cancer Institute | 2017-04-10 |
| CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (NCT03063450) | University of Southampton | 2017-03-28 |
| A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients (NCT02661100) | Case Comprehensive Cancer Center | 2017-01-01 |
| A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM (NCT03560973) | Gruppo Oncologico Italiano di Ricerca Clinica | 2016-12-22 |
| Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment (NCT01627795) | Oshadi Drug Administration | 2016-12-01 |
| Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (NCT02899299) | Bristol-Myers Squibb | 2016-11-29 |
| Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171) | Canadian Cancer Trials Group | 2016-11-11 |
| Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials (NCT02948413) | National Institutes of Health Clinical Center (CC) | 2016-11-10 |
| Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors (NCT02903914) | Incyte Corporation | 2016-09-14 |
| Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM (NCT02838745) | Baylor College of Medicine | 2016-09-01 |
| A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study (NCT02875548) | Epizyme, Inc. | 2016-08-30 |
| Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma (NCT02798536) | National Cancer Institute (NCI) | 2016-07-27 |
| Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma (NCT02860286) | Epizyme, Inc. | 2016-07-01 |
| Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma (NCT02613299) | Mayo Clinic | 2016-06-14 |
| MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma (NCT02592551) | Baylor College of Medicine | 2016-05-11 |
| Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors (NCT02611024) | PharmaMar | 2016-05-06 |
| Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients (NCT02716272) | Intergroupe Francophone de Cancerologie Thoracique | 2016-03-24 |
| Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma (NCT02613312) | Mayo Clinic | 2016-03-18 |
| Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma (NCT02611037) | H. Lee Moffitt Cancer Center and Research Institute | 2016-03-04 |
| Vinorelbine in Mesothelioma (NCT02139904) | Wales Cancer Trials Unit | 2016-03-01 |
| Staging Procedures to Diagnose Malignant Pleural Mesothelioma (NCT02648763) | Mayo Clinic | 2016-01-15 |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) (NCT02628067) | Merck Sharp & Dohme LLC | 2015-12-18 |
| Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) (NCT02610140) | Bayer | 2015-12-03 |
| Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication (NCT02511600) | M.D. Anderson Cancer Center | 2015-12-01 |
| Safety Study of MGD009 in B7-H3-expressing Tumors (NCT02628535) | MacroGenics | 2015-09-01 |
| Intrapleural Cryotherapy for Malignant Pleural Mesothelioma (NCT02464904) | Mayo Clinic | 2015-07-01 |
| Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma (NCT02293005) | M.D. Anderson Cancer Center | 2015-05-20 |
| Mesothelioma and Radical Surgery 2 (NCT02040272) | Royal Brompton & Harefield NHS Foundation Trust | 2015-05-01 |
| Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (NCT02414269) | Memorial Sloan Kettering Cancer Center | 2015-05-01 |
| Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome (NCT04792463) | Mohamed Abdel-Rahman | 2015-03-03 |
| Dendritic Cells Loaded With Allogeneous Cell Lysate in Mesothelioma Patients (NCT02395679) | Erasmus Medical Center | 2015-01-01 |
| Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma (NCT02385812) | University of Calgary | 2015-01-01 |
| Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy (NCT02062632) | Mayo Clinic | 2014-04-14 |